Answers are grounded in this paper and cite their sources.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiac disease caused by accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. TTR normally exists as a stable tetramer, but aging or disease-causing variants can reduce its stability. Dissociation of the tetramer into unstable monomers is an important step in amyloid formation. Tafamidis is a smallmolecule TTR kinetic stabilizer that binds to the thyroxine-binding sites of TTR and helps maintain the tetrameric structure. By reducing tetramer dissociation, tafamidis reduces the formation of new amyloid material. The clinical importance of tafamidis was demonstrated in the ATTR-ACT phase 3 trial. In 441 patients with ATTR-CM, tafamidis treatment was associated with lower all-cause mortality and cardiovascularrelated hospitalization compared with placebo over 30 months. Tafamidis also slowed deterioration in exercise capacity and health-related quality of life. Subsequent systematic reviews and meta-analyses have supported these findings. A 2023 meta-analysis involving 15 studies and 2765 patients found a lower risk of all-cause death or heart transplantation and a lower risk of composite adverse cardiovascular outcomes. A 2025 systematic review and meta-analysis also found lower mortality and fewer congestive heart failure exacerbations. More recent evidence has investigated cardiac imaging, biomarkers, myocardial strain and serial bone scintigraphy. A 2025 study reported reductions in cardiac [99mTc]Tc-DPD uptake after tafamidis treatment in patients with wild-type ATTR-CM. A 2026 systematic review reported potential stabilization of global longitudinal strain, preservation of functional status and lower all-cause mortality, although heterogeneity remained among studies. Overall, available evidence supports tafamidis as a disease-modifying treatment that slows the progression of ATTR-CM. Early diagnosis, appropriate patient selection, long-term treatment and further research into amyloid regression and disease monitoring remain important.
No takes yet. Share an insight, caveat, or question.
Ganesh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: